Home - Products - Cell Cycle/DNA Damage - CDK - Cdc7-IN-5

Cdc7-IN-5

CAS No. 1402057-86-6

Cdc7-IN-5( —— )

Catalog No. M32830 CAS No. 1402057-86-6

Cdc7-IN-5 is a potent inhibitor of Cdc7 kinase. Cdc7, a serine-threonine protein kinase enzyme, is essential for the initiation of DNA replication in the cell cycle.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	147	In Stock
5MG	227	In Stock
10MG	376	In Stock
25MG	601	In Stock
50MG	821	In Stock
100MG	1107	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Cdc7-IN-5
Note

Research use only, not for human use.
Brief Description

Cdc7-IN-5 is a potent inhibitor of Cdc7 kinase. Cdc7, a serine-threonine protein kinase enzyme, is essential for the initiation of DNA replication in the cell cycle.
Description

Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Cell Cycle/DNA Damage
Target

CDK
Recptor

CDK
Research Area

——
Indication

——

Chemical Information

CAS Number

1402057-86-6
Formula Weight

445.47
Molecular Formula

C25H23N3O5
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 12.5 mg/mL (28.06 mM; Ultrasonic (<60°C)
SMILES

CCOC(=O)C1=C(O\C(=C/c2c[nH]c3ncccc23)C1=O)N1CCc2ccc(OC)cc2C1
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Christian Andrew HASSIG, et al. Methods of treatment of cancer comprising cdc7 inhibitors. WO2019165473A1.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

PHA-848125

A potent, selective, brain penetrant and orally available dual CDK and TRK inhibitor with IC50 of 45 and 53 nM for CDK2/cyclin A and TrkA, respectively; shows cross-reactivity with other CDKs (CDK1/4/5/7), TrkB/C, Kit, Abl and PDGFR (IC50s<1 uM).
Senexin C

Senexin C is a novel orally active and specific CDK8/19 inhibitor with potential anticancer activity.Senexin C is more metabolically stable and potent than Senexin B. Senexin C inhibits the growth of MV4-11 leukaemia cells.
Voruciclib

A potent, selective and orally bioavailable CDK9 inhibitor with Ki of 0.63 nM and 1.68 nM for CDK9/cyclinT2 and CDK9/cyclinT1.

Sign In Join Free